Differences between RCI and placebo were nominally significant at week 8 in the low-disease-activity subgroups (Figs. 1 A, B) and at weeks 8, 16, and 24 in BICLA responders (Fig. 1 C).
← all excerpts
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
1
—
—